Fig. 1

Cytoplasmic eIF6 is overexpressed in OSCC and is associated with poor prognosis. (A) Expression of eIF6 in HNSCC patients based on the TCGA database. (B) Pathological scores on eIF6 were assessed in tumor (T) and non-tumor (NT) tissues. (C) Low expression of nucleus eIF6 was associated with poor prognosis (n = 22, p < 0.005). (D) No prognostic difference was observed in the nucleus and cytoplasmic co-expression of EIF6 between the low- and high-expression group. (E) Representative IHC micrographs of tumor microarrays sections stained with eIF6. (a) non-tumor tissue; (b) tumor tissue with eIF6 nucleus staining; (c) tumor tissue with eIF6 nucleus and cytoplasmic co-expression; (d) The weak, (e) moderate and (f) strong level of eIF6 staining were demonstrated. (F) The expression of eIF6 in OSCC patients with different T stage, N stage, clinical stage and pathological stage. (G) The survival curve of cytoplasmic eIF6 expression on prognosis. (H) The expression level of eIF6 protein in six tumor and adjacent non-tumor OSCC tissues. Density analysis of eIF6 signal with β-actin as the internal control. (I) The eIF6 mRNA expression in eight tumor and adjacent non-tumor OSCC tissues. In OSCC, the protein or mRNA expression of eIF6 is significantly higher than that of non-tumor tissues. All error bar values represent the SD. Scale bar, 100 μm. *P < 0.05, **P < 0.01, ***P < 0.001